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In systemic lupus erythematosus (SLE), perturbed immunoregulation underpins a
pathogenic imbalance between regulatory and effector CD4+ T-cell activity. However,
to date, the characterization of the CD4+ regulatory T cell (Treg) compartment in SLE
has yielded conflicting results. Here we show that patients have an increased frequency
of CD4+FOXP3+ cells in circulation owing to a specific expansion of thymically-derived
FOXP3+HELIOS+ Tregs with a demethylated FOXP3 Treg-specific demethylated region.
We found that the Treg expansion was strongly associated with markers of recent
immune activation, including PD-1, plasma concentrations of IL-2 and the type I
interferon biomarker soluble SIGLEC-1. Since the expression of the negative T-cell
signaling molecule PTPN22 is increased and a marker of poor prognosis in SLE, we
tested the influence of its missense risk allele Trp620 (rs2476601C>T) on Treg frequency.
Trp620 was reproducibly associated with increased frequencies of thymically-derived
Tregs in blood, and increased PD-1 expression on both Tregs and effector T cells (Teffs).
Our results support the hypothesis that FOXP3+ Tregs are increased in SLE patients as
a consequence of a compensatory mechanism in an attempt to regulate pathogenic
autoreactive Teff activity. We suggest that restoration of IL-2-mediated homeostatic
regulation of FOXP3+ Tregs by IL-2 administration could prevent disease flares rather
than treating at the height of a disease flare. Moreover, stimulation of PD-1 with specific
agonists, perhaps in combination with low-dose IL-2, could be an effective therapeutic
strategy in autoimmune disease and in other immune disorders.
Keywords: regulatory T cells (Tregs), systemic lupus erythematosus (SLE), autoimmunity, FOXP3, PTPN22
Arg620Trp, PD-1, type I interferon, immunotherapy
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an aggressive form of
autoimmune disease characterized by a break of self-tolerance
and chronic activation of the innate and adaptive immune
system. The variety of clinical manifestations associated with
SLE patients illustrates the heterogeneity of the condition, and
poses a significant challenge to our understanding of its common
etiology (1, 2). A defect in IL-2 signaling has been proposed
to be involved in the pathogenesis of SLE, disturbing the
homeostatic balance between regulatory (Treg) and effector T
cell (Teff) function that is essential to maintain self-tolerance
(3, 4). Furthermore, genetic evidence from recent genome-
wide association studies support a prominent role of the IL-2
signaling pathway in SLE (5). SLE shares a significant overlap
with the genetic susceptibility to type 1 diabetes (T1D) (6),
another autoimmune disease in which IL-2 signaling defects
play a central role in disease etiology. This genetic overlap
includes not only the classical HLA class II loci, but also key
immune genes, including PTPN22, IL2-IL21, IL2RA, IL10, IFIH1,
TYK2, TNFAIP3, IKZF3, IKZF1, and IL2RB-C1QTNF6, many of
which are directly implicated in the IL-2 and type 1 interferon
(IFN) pathways and T-cell activation, thereby supporting a
common genetically-regulated disease etiology between these
two autoimmune conditions.
Tregs characterized by the expression of the transcription
factor FOXP3, are critically dependent on IL-2 signaling for
survival and function, and have a key role in the maintenance
of self-tolerance and tissue integrity (7). Nevertheless, to date,
the exact role of FOXP3+ Tregs in the etiology of SLE remains
elusive, and there are inconsistent reports in the literature
regarding the numbers and function of Tregs in this disease
(8, 9). One explanation for this is the inconsistent definition
of a Treg phenotype, and the appreciation of the increasing
level of cellular and functional heterogeneity in this population
(10). One example is the identification of a non-conventional
subset of Tregs that express low levels of CD25, a key marker
along with CD127 that is widely used to define Tregs in flow
cytometric analyses, which we (11) and others (12–14) have
recently reported to be increased in SLE patients.
Understanding whether there is a genetically-intrinsic Treg
defect in SLE patients or whether Treg function is impaired
in the sense that a patient’s Tregs failed to prevent the disease
as a result of disease mechanisms in other cell types, for
example Teffs (15), is critical to assess the potential success and
development of Treg-targeted therapies in SLE. The PTPN22
gene, encoding the tyrosine phosphatase LYP and shown to
act as an inhibitor of T-cell receptor signaling, activation
and proliferation, has a common missense variant Arg620Trp
(rs2476601C>T), the minor allele of which (Trp620) predisposes
to several autoimmune diseases, including SLE and T1D (16).
Transcriptomics analyses of CD8+ T cells isolated from SLE
patients has revealed a distinct activated T-cell gene expression
signature associated with poor clinical prognosis (17). Of note,
elevated expression of PTPN22 was highly correlated with
this CD8+ T-cell gene expression signature, suggesting that
its upregulation could indicate an attempt to regulate Teff
hyperactivity during flaring autoimmunity (17). However, to date
the exact mechanism by which this missense allele is associated
with increased risk of autoimmunity remains uncertain (18),
with studies reporting different putative functional effects on
multiple cell types, including myeloid cells (19), as well as B and
T cells (20, 21).
In the present study, we have performed a detailed
flow cytometric characterization of the CD4+ FOXP3+ Treg
compartment in two cohorts of SLE patients, providing a
broad cross-sectional representation of the different stages
of disease activity. Our results show that thymically-derived
FOXP3+HELIOS+ Tregs, which by definition possess a fully
demethylated FOXP3 Treg-specific demethylated region (TSDR),
are expanded in SLE, especially during clinically active disease.
Furthermore, Tregs from SLE patients showed an activated
phenotype, and their frequency is strongly correlated with the
circulating levels of other markers of disease activity and chronic
inflammation, including soluble SIGLEC-1 (sSIGLEC-1) and IL-
2. We also report a previously uncharacterized association of the
PTPN22 Trp620 risk allele with increased Treg frequency in blood
and with elevated expression of the activation marker PD-1 on
both CD45RA− Treg and Teff CD4+ T-cell populations.
Taken together, our data support that FOXP3+ Treg
expansion in SLE is a marker of disease activity, likely as a
compensatory mechanism to control excess T-cell activity in
the context of a recent autoimmune reaction or flare. These
findings are particularly relevant in light of the recent reports
of clinical benefit of low-dose IL-2 therapy in active SLE (22–
24), and suggest that regulatory functions could be enhanced by
restoring the homeostatic balance of IL-2 signaling during the
phases of disease remission and delaying or preventing the next
flare. Moreover, our data also points to a central role of the PD-
1 signaling pathway in the pathogenesis of SLE, and suggests
that PD-1 immunomodulation, including PD-1 agonism, could
be a therapeutic option to inhibit the proliferation of pathogenic
autoreactive Teff cells and selectively restore Treg regulatory
homeostasis in SLE.
MATERIALS AND METHODS
Subjects
Discovery cohort (cohort 1) study participants included 34 SLE
patients recruited from Guy’s and St. Thomas’ NHS Foundation
Trust. All patients satisfied American College of Rheumatology
(ACR) SLE classification criteria and were allocated a disease
activity using SLEDAI-2K at the time of sampling. SLE patients
from cohort 1 were recruited from a clinic in which the severity
of disease was such that none the patients were on high dose
oral corticosteroids (>15 mg/day) or B-cell depleting therapy,
therefore representing a standard clinical cohort providing a
cross-sectional representation of patients with moderate to more
severe clinical activity on low-dose immunosuppressive drugs.
Healthy volunteers matched for age and sex were recruited from
the Cambridge BioResource (CBR). This discovery cohort 1
along with matched controls has been characterized in a previous
study, where we originally identified the expansion of a subset of
CD25low Tregs in SLE (11).
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TABLE 1 | Baseline characteristics of study participants.
Cohort N SLEDAI Age (years) Female N (%)
Median Range Median Range
Dicovery cohort (cohort 1)
SLE 34 4 0–14 36 20–72 32 (94.1%)
Healthy controls 24 – – 42 22–62 23 (95.8%)
Replication cohort (cohort 2)
SLE 41 – – 52 21–82 38 (92.7%)
Healthy controls 112 – – 49 26–78 82 (73.2%)
PTPN22 genotype-selected cohort (CBR)
1/ Whole blood Treg immunophenotyping
Arg620/Arg620 362 – – 47 19–78 239 (66.0%)
Arg620/Trp620 85 – – 49 31–77 62 (72.9%)
Trp620/Trp620 39 – – 55 35–73 23 (59.0%)
2/ Treg intracellular immunophenotyping
Arg620/Arg620 73 – – 50 26–78 52 (71.2%)
Arg620/Trp620 39 – – 49 31–77 30 (76.9%)
Trp620/Trp620 40 – – 55 35–73 23 (55.5%)
Baseline characteristics for the study participants stratified by the study cohorts.
SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus
disease activity index; CBR, Genotype selected healthy donors recruited from the
Cambridge BioResource.
A replication cohort (cohort 2) of 41 SLE patients and 112
healthy volunteers was recruited from the CBR. The SLE patients
from cohort 2 were recruited specifically for this study outside
their regular clinic visits, and represent a population-based
cohort with good disease management that were otherwise well
at the time of bleeding. No additional disease information or
ancestry data was available for this cohort of patients.
For the analysis of PTPN22 Arg620Trp, 551 subjects of self-
reported white ethnicity were selected by genotype from the
CBR. A subset of 152 subjects, including 40 homozygotes for
the missense PTPN22 Trp620 allele, 40 heterozygotes and 73
common Arg620 homozygotes were selected to investigate the
effect of the PTPN22 Arg620Trp variant on T-cell phenotypes.
All adult healthy volunteers reported no family history of
autoimmune disease. Baseline characteristics for all participating
subjects are summarized in Table 1.
Ethics Statement
All samples and information were collected with written and
signed informed consent. Informed consent was obtained from
SLE patients (cohort 1—REC Ref: 07/H0718/49). Adult SLE
patients (cohort 2) and matching adult healthy volunteers
were enrolled from the CBR. The study was approved by
the local Peterborough and Fenland research ethics committee
(05/Q0106/20 and 08/H0308/153). The study conformed to the
Declaration of Helsinki and all local ethical requirements.
Peripheral Blood Mononuclear Cell Sample
Preparation
Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll gradient centrifugation (Lymphoprep; StemCell
Technologies) and cryopreserved in 10% heat-inactivated human
AB serum (Sigma), as described previously (25). SLE patients
and healthy volunteers were recruited contemporaneously
and samples were processed and stored by the same
investigators to prevent spurious findings caused by differential
sample preparation.
Flow Cytometry
For intracellular immunostainings, PBMCs were rapidly thawed
at 37◦C in a water bath, resuspended in X-VIVO 15 (Lonza)
+1% heat-inactivated, filtered, human AB serum (Sigma).
PBMCs were immunostained with fluorochrome-conjugated
antibodies against surface-expressed markers for 30min at
room temperature. Cells were washed and stained for viability
discrimination using the Fixable Viability Dye eFluor 780
(eBioscience) for 20min at 4◦C. Fixation and permeabilization
was performed using the FOXP3 Fix/Perm Buffer Set
(eBioscience) according to the manufacturer’s instructions,
and cells were then immunostained with fluorochrome-
conjugated antibodies against intracellular markers for 45min at
room temperature. To minimize the effect of technical variation
of the assay and biological covariates like age and sex, samples
were assessed in five batches of 40 on each day over a period
of two weeks. Each batch was composed of eight SLE patients
and 32 healthy donors (including 16 PTPN22 Arg620 common
homozygotes, 8 PTPN22 heterozygotes and 8 PTPN22 Trp620
homozygotes) matched as closely as possible for age, sex and
time of collection. Because we were testing the effect of the rare
PTPN22 Trp620 non-synonymous allele on Treg frequency, we
excluded the rare genotype-selected Trp620 homozygous donors
from all SLE vs. healthy controls analyses.
For surface immunostainings, 150 µl of whole blood was
incubated with fluorochrome-conjugated antibodies at room
temperature for 45min, within 4 h of phlebotomy. Red cells
were then lysed (BD FACS Lysing Solution) and washed prior to
sample acquisition.
Information on all fluorochrome-conjugated antibodies and
immunostaining panels used in this study is provided in
Supplementary Table 1. All experiments were performed in an
anonymized, blinded manner without prior knowledge of disease
state. Immunostained samples were acquired using a BD Fortessa
(BD Biosciences) flow cytometer with FACSDiva software (BD
Biosciences) and analyzed using FlowJo (Tree Star, Inc.). Dead
cells were excluded based on the eFluor780 Fixable Viability Dye.
Samples from cohorts 1 and 2 were processed and acquired on
the flow cytometer within a period of 11 months of each other.
Analysis of the FOXP3 TSDR
Demethylation
Three SLE patients from cohort 2 (enrolled from CBR) were
recalled based on the presence of a type 1 IFN signature
and high frequency of CD25low FOXP3+ T cells. Total
CD4+ T cells were enriched from 50ml whole blood using
RosetteSep (StemCell Technologies) and immunostained
with fluorochrome-conjugated antibodies as described
above (see Supplementary Table 1). Memory CD45RA−
FOXP3+HELIOS+ Tregs from the (i) CD127lowCD25low and (ii)
CD127lowCD25high subpopulations and a negative control subset
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of CD45RA− CD127+CD25int/low Teffs were FACS sorted using
a BD Aria Fusion flow cytometer (BD Biosciences). Methylation
of the FOXP3 TSDR was performed using a next-generation
sequencing method, as described previously (26).
Plasma Soluble SIGLEC-1 and IL-2
Measurements
Soluble SIGLEC-1 (sSIGLEC-1) concentrations were measured
in plasma samples from all study participants using a time-
resolved fluorescence immunoassay, as described previously (27).
Circulating IL-2 concentrations were measured in plasma
samples from the 41 SLE patients from cohort 2 by Single-
Molecule Array (SIMOA) digital ELISA (Quanterix) according to
the manufacturer’s instructions. Measurements were performed
in plasma samples that had only undergone one freeze-
thaw cycle.
In vitro Treg Suppression and Teff
Proliferation Assays
Total Tregs (CD4+ CD127lowCD25hi) and autologous memory
Teffs (mTeffs; CD4+CD45RA− CD127+CD25int−low) or naïve
Teffs (nTeffs; CD4+CD45RA+ CD127+CD25int−low) were FACS
sorted from cryopreserved PBMCs from a subset of 27 common
Arg620 homozygous and 24 age- and sex-matched rare Trp620
homozygous donors into 96 well plates using a BD FACS Aria
II. Samples were stimulated with anti-CD2/3/28 beads (Miltenyi
Biotec) and incubated at 37◦C, 5% CO2 for 6 days. Proliferation
was assessed by the addition of 0.5 µCi/well [3H]thymidine
(PerkinElmer, Waltham, MA) for the final 18 h co-culture.
All conditions were run in quintuplicate and proliferation
readings ([3H]thymidine incorporation rate—CPM) averaged.
Tregs were stimulated in the absence of mTeffs in triplicate,
and no proliferation above background was observed in any
of the donors. The percentage suppression in each culture was
calculated using the following formula: % suppression = 100
– [(CPM in the presence of Tregs ÷ CPM in the absence
of Tregs)× 100].
Transcriptional Profiling of Total CD4+
T Cells
Gene expression profiling was performed by NanoString,
using the pre-designed nCounter Human Immunology v2
Panel (NanoString Technologies). Total CD4+ T cells from a
subset of (i) four SLE patients with previously identified high
transcriptional IFN signature, (ii) two SLE patients with low
IFN signature, and (iii) four healthy controls, were obtained by
negative selection (StemCell Technologies) from cryopreserved
PBMCs. A total of 25,000 cells were collected into RLT lysis buffer
(Qiagen) following in vitro stimulation for 120min with PMA
and ionomycin cocktail without addition of protein transport
inhibitors (eBiosciences). RNA was extracted using the RNAeasy
Micro Plus kit (Qiagen), with gDNA cleanup, and hybridized to
the NanoString CodeSets, following manufacturer’s instructions.
Expression levels were assessed using an nCounter Sprint
instrument (NanoString Technologies). Data were processed
using the nSolver Analysis Software following normalization of
the raw read counts to the geometric mean of positive control
spike-ins, and the gene expression of 15 selected housekeeping
genes that were found to have low variability following in vitro
stimulation, as previously described (28).
Targeted Single-Cell RNA-Sequencing
Analyses
Single-cell RNA sequencing data, was obtained from one SLE
patient with an expanded CD25lowFOXP3+ Treg population,
one type 1 diabetes (T1D) patient and one healthy control
(HC), presented in Trzupek et al. (29). Briefly, simultaneous
mRNA expression of 397 genes (Human Response Panel; BD
Biosciences) and protein expression of 24 T-cell expressed
targets (see Supplementary Table 1), were assessed at the
single-cell level using the BD Rhapsody and AbSeq system
(BD Biosciences), as previously described (29). Flow sorted
CD4+ T-cell subsets from each donor were barcoded using
oligo-conjugated antibodies (single-cell multiplexing kit; BD
Biosciences). For this study, we extracted and reanalyzed
the data from sorted CD127lowCD25low (N = 7,115) and
CD127lowCD25hi (N = 7,711) T cells passing QC. Detailed
description of sorting strategy, library preparation and
sequencing is presented in Trzupek et al. (29). Data analysis
and QC was performed following the BD Biosciences Rhapsody
pipeline (BD Biosciences) and the R package Seurat 3.0 (30).
Uniform Manifold Approximation and Projection (UMAP)
was used for dimensionality reduction. Differential expression
analysis was performed using a tailored hurdle model from
MAST package (31) used by Seurat.
Genotyping and Quality Control
rs2476601 genotypes for the 551 PBMC bank subjects were
obtained using the Illumina ImmunoChip. Genotyping of
196,524 SNPs was performed in two batches of 191 and
360 samples. 59,556 SNPs were excluded from the analysis
because they were either monomorphic in at least one of the
genotyping batches (n= 40,091) or corresponded to A/T or G/C
polymorphisms (n = 19,465), for which the correct genotype
assignment could not be unambiguously determined. SNPs were
tested for departure from Hardy-Weinberg equilibrium within
either batch or with batches combined, and 2,183 with significant
departures at P < 10−5 were discarded. Batches were tested
against each other for genotypic differences using Fisher’s Exact
Test (3 × 2 genotypic test) and 674 SNPs with significant
genotype differences at P < 10−5 were discarded. rs2476601 was
not subjected to these quality control (QC) steps as subjects
had been selected for inclusion in the PBMC bank based using
their genotypes at this position. After removal of 10,073 SNPs
with missingness > 1%, the remaining 124,038 SNPs were used
to apply subject-level QC filters. The 3 subjects found to have
missing genotypes at > 1% of SNPs were discarded, in addition
to 15 that were Principal Component (PC) outliers, leaving 533
subjects. Outliers were defined as individuals with >6 standard
deviations from the mean for any of the top 10 PCs, as computed
from the post-QC SNP data (using 93,546 SNPs with MAF
> 5%). After outlier removal, PCs were recomputed and the
process iterated until no outliers remained. QC procedures were
performed in PLINK (32) and R.
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Statistical Analyses
Statistical analyses were performed using Prism software
(GraphPad), PLINK and R. Frequency of the interrogated
immune subsets were compared between SLE patients and
healthy donors or PTPN22 genotype groups using two-tailed
Student’s t-tests. The correlations between immune parameters
and the plasma concentrations of sSIGLEC-1 and IL-2 were
calculated using linear regression analysis. Given that plasma
protein concentrations showed moderate to strong right skew
that violated the assumption of normality, the phenotypes were
log-transformed before statistical testing. The effects of age,
sex and time of collection were controlled by the experimental
design used in this study and, therefore, not included as
additional covariates.
The relationship between Treg frequency in blood and
rs2476601 genotype was analyzed by regressing the adjusted Treg
frequency measurement against the number of minor alleles.
This was performed using 486 individuals who had both Treg
frequency and genotype data post-QC. For subjects who had
multiple Treg frequency measurements (n = 20), the mean was
used. To account for a potential systematic variation in the
estimation of the Treg frequencies by flow cytometry during
the duration of the study, Treg frequencies were corrected for
number of days since the first measurement and for batch
(there were two batches of 383 and 120 individuals), by linearly
regressing out these variables. Linear regression was used to
estimate the effect of each missense PTPN22 Trp620 allele
(rs2476601) with Treg frequency, for the 486 individuals with
both Treg frequency and rs2476601 genotypes available. Effects of
genetic ancestry and relatedness between subjects were corrected
for via the inclusion of 10 PCs computed using the 124,038
SNPs and 533 subjects with genotypes remaining after QC. A
similar analysis was done to assess the relationship between the
frequency of the CD45RA+ naïve and CD45RA− memory Tregs
and rs2476601 genotypes (n= 485; one donor was excluded from
this analysis for missing CD45RA flow cytometric data). Age
was strongly correlated with these phenotypes, so was regressed
out in addition to batch and number of days since the start of
the experiment.
Replication was performed using 3,437 Sardinian PBMC
samples and the combined 3,923 individuals were meta-analyzed
using Fisher’s method for combining P-values and inverse-
variance weighting of parameter estimates. Summary statistics
were scaled by the Treg standard deviation prior to meta-analysis
before rescaling final estimates via the estimate from the UK
group (SD= 1.77).
RESULTS
Frequency of CD4+ FOXP3+ Tregs Is
Increased in Peripheral Blood From SLE
Patients
To investigate the circulating CD4+ Treg compartment
of SLE patients, we performed a detailed flow cytometric
characterization of cryopreserved PBMCs from two cohorts of
patients: (i) a clinic-attending—cohort 1- of patients recruited at
the time of their regular clinic visit; and (ii) a population-based
cohort—cohort 2—of patients recruited outside of their regular
clinic visits through the Cambridge BioResource. To avoid
potential discrepancies caused by how the Treg compartment
was defined, in this study, we have delineated Tregs both through
their surface expression of IL-7R/CD127 and IL-2RA/CD25
(CD127lowCD25hi Tregs), or by further restricting to the cells
that express the canonical Treg transcription factor FOXP3
(FOXP3+ CD127lowCD25hi Tregs; Figure 1A). Regardless of
how Tregs were delineated, we found a consistent increase
in the frequency of both CD127lowCD25hi (5.7 vs. 8.5% and
6.3 vs. 7.5% in cohorts 1 and 2, respectively; Figure 1B) and
FOXP3+ CD127lowCD25hi (4.6 vs. 7.3% and 4.6 vs. 5.4% in
cohorts 1 and 2, respectively; Figure 1C) Tregs in blood from
SLE patients compared to age-matched healthy volunteers.
The increased frequency of Tregs was more pronounced in
patients from cohort 1, likely reflecting the increased level
of disease activity in that cohort of patients. In addition, the
expansion of the FOXP3+ Tregs in SLE patients was higher in
the memory CD45RA− compartment (Figures 1D,E) compared
to the naïve CD45RA+ compartment (Figures 1D,F), suggesting
that the observed increased Treg frequency is not a direct
effect of an increased thymic Treg output in SLE patients, but
rather is a regulatory response to the inflammation caused by
activated immune cells mediating the autoimmune disease. In
particular, increased IL-2 production by autoantigen-specific
Teffs could promote the expansion of Tregs activated in the local,
inflammatory environment.
Consistent with our previous data (11), we confirmed that
the expansion of FOXP3+ cells was also observed within the
CD127lowCD25low compartment (Figures 2A,B). Frequencies of
CD25lowFOXP3+ among total CD4+ T cells are usually very low
in healthy donors (0.04–1.22%; Figure 2C), but were found to
be substantially increased among SLE patients, with frequencies
as high as 14.6% of total CD4+ T cells (Figure 2C). We also
noted that the frequency of CD25lowFOXP3+ Tregs displayed a
bimodal distribution among SLE patients, which was particularly
noteworthy within the clinic-attending patients from cohort
1 (Figure 2C). In agreement with the observed expansion of
FOXP3+ T cells in SLE patients in both the conventional CD25hi
and the non-conventional CD25low subpopulations, we observed
a significant increase in the frequency of total CD4+ FOXP3+
cells in SLE patients (Figure 2D).
Expanded Tregs in SLE Patients Are
Predominantly FOXP3+HELIOS+ and Are
Demethylated at the FOXP3 TSDR
To further investigate the origin of the expanded CD45RA−
FOXP3+ Tregs in SLE patients we further stratified the
distribution of both CD25low (Figure 3A) and CD25hi
(Figure 3B) Treg populations according to the expression of
HELIOS, a key transcription factor required to maintain the Treg
transcriptional programme and suppressive function (33). In
both subsets, we found a higher frequency of FOXP3+HELIOS+
Tregs in blood from SLE patients compared to matched healthy
volunteers (Figures 3C,D). We have shown previously that
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FIGURE 1 | Regulatory CD4+ T cell (Treg) frequency is increased in the circulation of SLE patients. (A) Gating strategy for the delineation of CD4+ regulatory T cells
(Tregs). (B,C) Scatter plots depict the frequency (geometric mean ± 95% CI) of CD127lowCD25hi Tregs (B), and CD127lowCD25hi FOXP3+ Tregs (C) in PBMCs
isolated from SLE patients (depicted in red) and matching healthy volunteers (depicted in blue). (D) Gating strategy for the delineation of the CD45RA+ naïve and
CD45RA− memory CD4+ T-cell compartments. (E,F) Scatter plots depict the frequency (geometric mean ± 95% CI) of memory CD45RA− (E), and naïve CD45RA+
(F) CD127lowCD25hi FOXP3+ Tregs. Data were obtained from a discovery clinic-attending cohort (cohort 1) consisting of 34 SLE patients and 24 healthy volunteers,
and from a population-based replication cohort (cohort 2) consisting of 41 SLE patients and 112 healthy volunteers. P-values were calculated using two-tailed
Student’s t-tests comparing the frequency of the assessed immune subsets in patients and controls. SLE, systemic lupus erythematosus; HC, healthy control; ns,
not significant.
essentially all FOXP3+HELIOS+ Tregs are demethylated at
the FOXP3 TSDR (11) In contrast, we found no evidence for
an increase in the frequency of FOXP3+HELIOS− Tregs, a
subset in which only a portion of the cells have a demethylated
FOXP3 TSDR (11) and that we have previously shown to
be enriched in cells with the capacity of producing pro-
inflammatory cytokines (28), in either the CD25low (Figure 3E)
or CD25hi (Figure 3F) compartments. These data indicate
that the increased Treg frequency observed in SLE patients
results from the specific expansion of thymically-derived
FOXP3+ Tregs.
To further confirm this hypothesis, we recalled
three SLE patients from cohort 2 that showed an
expanded FOXP3+ Treg compartment, and assessed
the epigenetic profile at the FOXP3 locus in freshly
isolated CD25low and CD25hi FOXP3+HELIOS+ Tregs
(Supplementary Figure 1A). In sharp contrast with
CD25−CD45RA− memory Teff cells, we found that
both CD25low and CD25hi CD45RA−FOXP3+HELIOS+
Tregs displayed a fully demethylated FOXP3 TSDR
(Supplementary Figure 1B), consistent with a stable constitutive
expression of FOXP3 and therefore a thymic origin and
Treg identity.
Single-Cell RNA-Sequencing Reveals
Phenotypic Similarities Between ex vivo
Isolated CD25lowFOXP3+ T Cells and
Conventional CD25hiFOXP3+ Tregs
Currently there are no identified surface markers that allow
the isolation of the identified CD25lowFOXP3+ T cells,
which precludes the unequivocal characterization of their
putative suppressive capacity. This is particularly relevant in
SLE patients with active disease, where the disease-specific
environment could affect cell function. Therefore, to further
investigate the nature of CD25lowFOXP3+ T cells, we employed
a recently developed targeted single-cell RNA-sequencing
approach combining mRNA and protein quantification (29), to
characterize the FOXP3+ cells within both CD127lowCD25low
and CD127lowCD25hi populations from one SLE patient
displaying an expanded Treg compartment, as well as two
control donors (one type 1 diabetic and one healthy donor).
Clustering analysis of the combined mRNA and protein
expression from all ex vivo isolated CD127lowCD25low (n
= 7,115) and CD127lowCD25hi (n = 7,711) cells, revealed
diverse functional T-cell subsets, clustering along a naïve-
memory differentiation axis, including distinct Treg clusters
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FIGURE 2 | Frequency of FOXP3+ T cells in SLE patients is increased in both CD25low and CD25hi CD4+ T-cell subsets. (A) gating strategy for the delineation of the
CD25lowFOXP3+ Treg subset. (B,C) Scatter plots depict the frequency (geometric mean ± 95% CI) of CD25lowFOXP3+ Tregs in SLE patients (red) and matching
healthy volunteers (blue), defined as the frequency of FOXP3+ cells among CD127lowCD25low T cells (B) or as the frequency of CD127lowCD25lowFOXP3+ T cells
among total CD4+ T cells (C). (D) Scatter plot depicts the frequency (geometric mean ± 95% CI) of total CD4+FOXP3+ Tregs in SLE patients (red) and matching
healthy volunteers (blue), defined as the frequency of FOXP3+ cells among total CD4+ T cells. Data were obtained from a discovery clinic-attending cohort (cohort 1)
consisting of 34 SLE patients and 24 healthy volunteers, and from a population-based replication cohort (cohort 2) consisting of 41 SLE patients and 112 healthy
volunteers. P-values were calculated using two-tailed Student’s t-tests comparing the frequency of the assessed immune subsets in patients and controls. SLE,
systemic lupus erythematosus; HC, healthy control.
marked by the expression of FOXP3 and IKZF2 (encoding
HELIOS; Figures 4A–C and Supplementary Figure 2A). To
identify FOXP3+ cells within the two assessed T-cell populations,
we then isolated cells with detectable FOXP3 expression. We
noted that in the SLE patient 68.2% of CD127lowCD25hi
and 12.8% CD127lowCD25low T cells expressed FOXP3 at
the mRNA level (Figure 4D). This compared to 83.8 and
20.8%, respectively for the expression of FOXP3 detected at
the protein level by flow cytometry in the same patient, and
is consistent with the lower sensitivity of mRNA detection,
especially of lowly expressed genes, by scRNA-seq methods.
Importantly, CD25lowFOXP3+ cells clustered together with the
conventional CD25hiFOXP3+ Tregs, with similar distribution
across the different identified Treg subsets (Figure 4E). The
only notable exception was a marked absence of CD45RA+
naïve Tregs among CD25lowFOXP3+ cells, which is consistent
with the activated phenotype previously observed among
this subset (11). Furthermore, differential expression analysis
revealed a distinct upregulation of classical Treg signature genes,
including IL-2RA and HELIOS, within CD25lowFOXP3+ as
compared to their respective CD25lowFOXP3− counterparts
(Figure 4F). A very similar Treg signature was observed when
comparing conventional CD25hiFOXP3+ Tregs with the same
CD25lowFOXP3− Teff cell population (Figure 4G), which further
supports the Treg function and identity of the majority of ex vivo
isolated CD25lowFOXP3+ cells.
Nevertheless, we note that ∼48.2% of CD25lowFOXP3+
cells clustered within non-Treg subsets, compared to only
8% within conventional CD25hiFOXP3+ Tregs (Figure 4E).
These results demonstrate the increased heterogeneity of the
CD127lowCD25low population and the need to identify further
surface markers to isolate CD25lowFOXP3+ cells in order to
assess their function. Furthermore, these data also indicate that
a proportion of CD25lowFOXP3+ cells could represent either
non-conventional Treg subsets or activated Teffs, transiently
upregulating FOXP3 at the protein level. Of note, the relative
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FIGURE 3 | Expanded FOXP3+ Tregs in SLE patients are predominantly HELIOS+. (A,B) Gating strategy for the delineation of the CD45RA− CD25low (A) and CD25hi
(B) Treg subsets stratified by the expression of the canonical Treg transcription factors FOXP3 and HELIOS. (C,D) Scatter plots depict the frequency (geometric mean
± 95% CI) of CD25low FOXP3+HELIOS+ (C), and CD25hi FOXP3+HELIOS+ (D) Tregs in SLE patients (red) and matched healthy volunteers (blue). (E,F) Scatter plots
depict the frequency (geometric mean ± 95% CI) of CD25low FOXP3+HELIOS− (E), and CD25hi FOXP3+HELIOS− (F) Tregs in SLE patients and matched healthy
volunteers. Data were obtained from a discovery clinic-attending cohort (cohort 1) consisting of 34 SLE patients and 24 healthy volunteers, and from a
population-based replication cohort (cohort 2) consisting of 41 SLE patients and 112 healthy volunteers. P-values were calculated using two-tailed Student’s t-tests
comparing the frequency of the assessed immune subsets in patients and controls. SLE, systemic lupus erythematosus; HC, healthy control; ns, not significant.
distribution of either CD25hiFOXP3+ CD25lowFOXP3+ cells
within the different T-cell clusters was similar between the
SLE and the two control donors (Supplementary Figures 2B,C),
which suggests there is no evidence for a disease-specific
enrichment in putative activated CD25lowFOXP3+ Teff subsets.
Memory CD25hiFOXP3+HELIOS+ Tregs
From SLE Patients Display an Activated
Phenotype
Having established that CD45RA− CD25hiFOXP3+HELIOS+
Tregs represented the majority of expanded Tregs in
SLE patients, we next performed a detailed phenotypic
characterization of this subset to gain further insight into
their potential function and causes of expansion. The main
distinguishing features of CD25hiFOXP3+HELIOS+ Tregs
isolated from SLE patients were the increased expression of
the activation marker PD-1 (Figure 5A) and the reduced
expression of CD25 on a per cell basis (Figure 5B). The
phenotypic changes associated with CD25hi FOXP3+HELIOS+
memory Tregs suggest that these cells have expanded in SLE
patients in response to an inflammatory, autoimmune reaction;
the chronic stimulation could cause CD25 levels on Tregs
to decrease due to IL-2RA mRNA down-regulation or to
cleavage of the CD25 molecule from the cell surface. Such
mechanisms to decrease CD25 levels could account for the
increased frequency of CD45RA− CD25lowFOXP3+HELIOS+
Tregs in SLE patients. Consistent with this hypothesis, we
found a very strong correlation between the frequency
of PD-1+ cells in CD45RA− CD25hiFOXP3+HELIOS+
Tregs and CD45RA− Teffs in both SLE patients and
healthy donors (Supplementary Figures 3A,B). suggesting
that expression of PD-1 is a sensitive marker of immune
activation on both populations and that as more Teffs
are activated there is a compensatory, homeostatic,
increase in Treg activation. We noted that expression
levels of PD-1 on CD45RA− Teffs are higher than their
CD45RA− FOXP3+HELIOS+ Treg counterparts in both
patients and healthy donors, and similar MFI values were
observed for the two subsets between patients and controls
(Supplementary Figures 3C,D).
Conversely, we found no increase in the frequency of TIGIT−
Tregs (Figure 5C), a subset of cells that we have previously
shown to contain cytokine-producing T cells and to be enriched
for a subset of Th17-like Tregs (28). Furthermore, we did
not find significant changes associated with the expression
of conventional functional Treg markers, CD15s, CD226,
CD161, and HLA-DR (Supplementary Figure 4) or in the
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FIGURE 4 | Single-cell RNA-sequencing reveals phenotypic similarities between CD25lowFOXP3+ T cells and conventional CD25hiFOXP3+ Tregs. (A) Uniform
manifold approximation projection (UMAP) plot depicting clustering of all captured CD4+ single cells using the combined proteomics and transcriptomics data. Data
were extracted from a targeted single-cell RNA-sequencing dataset (ref. 29), and depicts the analysis of pre-sorted CD127lowCD25hi (N = 7,711) and
CD127lowCD25low (N = 7,115) T cells from one SLE patient and two control donors, including one type 1 diabetes (T1D) patient and one healthy donor.
(B) Expression levels of the CD45RA (black to green) and CD45RO (black to red) isoforms using oligo-conjugated antibodies. (C) Expression of the canonical Treg
transcription factors FOXP3 and HELIOS in the identified resting CD4+ T-cell clusters. (D) Detection of FOXP3+ cells (as assessed by the expression of >=1 copy of
FOXP3 in each single cell) in either the pre-sorted CD127lowCD25hi (blue) or CD127lowCD25low (red) populations. Relative frequencies of FOXP3+ cells in SLE and
control donors is indicated in the figure. (E) Frequency of FOXP3+ cells from either the CD127lowCD25hi or CD127lowCD25low populations in each identified regulatory
T cell (Treg) or effector T cell (Teff) cluster. Clusters were ordered according to their relative positioning along the naïve to memory (Mem) differentiation axis.
(F,G) Volcano plots depict the differential expression of the assessed genes at the mRNA (N = 397 genes) and protein (N = 24) level between: (i) CD127lowCD25low
FOXP3+ vs. CD127lowCD25low FOXP3− T cells (F); and (ii) CD127lowCD25hi FOXP3+ Tregs vs. CD127lowCD25low FOXP3− T cells (G).
expression of the proliferation marker Ki-67 (Figure 5D)
in CD45RA− CD25hiFOXP3+HELIOS+ Tregs from SLE
patients. Together, these data reveal that the increased
frequency of FOXP3+ Tregs observed in SLE patients is
not caused by a selective expansion of non-conventional or
peripherally induced Tregs, which could be less functional
or even promoting the production of pro-inflammatory
cytokines, but rather by the expansion of bona-fide thymically-
derived FOXP3+HELIOS+ Tregs, showing the hallmarks of
suppressive functions.
Similarly to the phenotype of CD45RA− FOXP3+HELIOS+
Tregs, CD45RA− Teffs from SLE patients also showed
evidence for increased expression of T-cell activation and
proliferation markers, namely PD-1, Ki-67, TIGIT and CD15s
(Supplementary Figure 5). The increased expression of
these markers was only significantly increased in the clinic-
attending cohort 1, and therefore could reflect aggressive
autoreactive Teff cell and chronic activation in patients with
active disease flares.
Frequency of FOXP3+ Tregs in SLE
Patients Is Highly Correlated With
Increased Circulating Levels of Type I
Interferon and IL-2
Recently, we have reported that the plasma concentration of the
soluble form of the adhesion receptor SIGLEC-1 (sSIGLEC-1) is
sensitive marker of the type I IFN transcriptional signature (27).
In addition, we have shown that the concentration of sSIGLEC-1
was also associated with increased disease activity in SLE patients.
In the present study, we have found a very strong correlation
between the concentration of sSIGLEC-1 in plasma and the
frequency of CD25lowFOXP3+ Tregs in SLE patients, but not
in healthy controls, in both the clinic-attending (r = 0.66, P =
2.5 × 10−5; Figure 6A) and in the population-based (r = 0.65,
P = 5.0 × 10−6; Figure 6B) cohorts. This association was not
restricted to the CD25lowFOXP3+ subset, but also observed with
total CD4+ FOXP3+ Tregs (Figures 6C,D), particularly in the
clinical cohort (r = 0.71, P = 2.2 × 10−6; Figure 6C). These
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FIGURE 5 | Memory FOXP3+HELIOS+ Tregs from SLE patients display hallmarks of recent immune activation. (A–D) Representative histograms and summary
scatter plots depict the frequency (geometric mean ± 95% CI) of: (i) PD-1+ (A); (ii) CD25 mean fluorescence intensity (B); (iii) TIGIT− (C); and (iv) Ki-67+ (D) cells within
CD45RA− CD25hi FOXP3+HELIOS+ Tregs. Data were obtained from a discovery clinic-attending cohort (cohort 1) consisting of 34 SLE patients (depicted in red) and
24 healthy volunteers (depicted in blue) and from a population-based replication cohort (cohort 2) consisting of 41 SLE patients and 112 healthy volunteers. Samples
from cohorts 1 and 2 were processed within a period of 11 months of each other. For each parameter an illustrative histogram is provided as a reference depicting the
expression of the marker in the CD45RA+ FOXP3+HELIOS+ naïve Treg population (depicted in gray). P-values were calculated using two-tailed Student’s t-tests
comparing the frequency of the assessed immune subsets in patients and controls. SLE, systemic lupus erythematosus; HC, healthy control; ns, not significant.
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FIGURE 6 | FOXP3+ Treg expansion is a marker of recent autoimmune reaction. (A,B) Correlation between the frequency of CD25lowFOXP3+ Tregs in blood and the
circulating concentration of the plasma type I interferon (IFN) marker soluble SIGLEC-1 (sSIGLEC-1). Data shown depict the correlation in SLE patients (red) and
matched healthy volunteers (black) in either the discovery clinic-attending cohort—cohort 1 (A) or the replication population-based cohort—cohort 2 (B). (C,D) Data
shown depict the correlation between the total CD4+FOXP3+ CD45RA− memory Tregs and the plasma concentration of sSIGLEC-1 in cohort 1 (C) and cohort 2 (D).
(E,F) Data shown depict the correlation between the frequency of CD25lowFOXP3+ (E) or total FOXP3+ (F) CD45RA− memory Tregs and the plasma concentration of
IL-2 measured in the 41 SLE patients from cohort 2. The correlation coefficients (r) and the respective P-values from the linear regression in SLE patients and healthy
controls are shown in the plots.
findings demonstrate that the expansion of FOXP3+ Tregs in SLE
is correlated with increased type I IFN signaling, which is known
to play a major etiological role in the progression of the disease.
To investigate if the observed Treg expansion could also be
recapitulated at the transcriptional level, we next investigated
the transcriptional profile of total CD4+ T cells in a subset
of (i) four SLE patients where we had previously detected
a high transcriptional IFN signature (IFNhi) in total PBMCs
(27); (ii) two SLE patients with low IFN signature (IFNlow);
and (iii) four healthy donors (Supplementary Figure 6A and
Supplementary Table 2). Although it is well-established that
myeloid cells are the main contributors to the transcriptional
whole blood IFN signature observed in SLE patients, we observed
that the expression of two canonical IFN signature genes
(MX1 and IFH1), but not a housekeeping gene (HPRT1) were
highly correlated with the quantitative IFN signature score
(Supplementary Figure 6B), indicating that total CD4+ T cells
are also contributing to this peripheral transcriptional signature.
Furthermore, in agreement with the observed FOXP3+ Treg
expansion in patients with increased type I IFN signaling, we
were able to detect increased expression of the classical Treg
signature genes FOXP3 and IKZF2 (encoding HELIOS) in IFNhi
patients. In contrast, mRNA expression of other markers of
activated Tregs, such as PDCD1 (encoding PD-1), IL-2RA, and
HLA-DRA, were not associated, which is consistent with their
more heterogeneous expression pattern in other activated CD4+
Teff subsets (Supplementary Figures 6C–E). Further supporting
the correlation between protein and mRNA levels, we detected
a remarkable correlation between the expression of FOXP3 and
IKZF2 with the frequency of FOXP3+ cells in both total CD4+
or CD127lowCD25low T cells (Supplementary Figures 6F,G),
demonstrating that the observed Treg expansion in SLE patients
can also be detected through the transcription of classical Treg
signature genes in circulating CD4+ T cells.
In addition tomeasuring the levels of type I IFN in circulation,
we have also employed a sensitive single molecule digital ELISA
assay to measure the circulating concentrations of IL-2 in plasma
samples from all 42 SLE patients in the population-based cohort
2. We found a strong correlation between the plasma IL-2
concentration and frequency of both CD25lowFOXP3+ (r= 0.63,
P = 1.6 × 10−5; Figure 6E) and total CD4+ FOXP3+ Tregs (r
= 0.64, P = 1.1 × 10−6; Figure 6F). Although we could not
attempt to replicate these findings in the clinic-attending cohort
of patients due to insufficient plasma volume, it is noteworthy
that such a strong correlation could be observed even in samples
with relatively modest concentrations of IL-2, which our data
suggest could be even higher during flares of the disease.
The PTPN22 Autoimmune Risk Allele Trp620
Is Associated With Increased Frequency of
Tregs in Blood
The higher expression of PTPN22 in CD8+ Teffs in SLE patients
prone to flaring could be a mechanism to negatively regulate
CD8+ Teff activation to reduce aggressive autoimmunity (17).
To investigate whether the autoimmune-associated PTPN22
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FIGURE 7 | The autoimmunity missense PTPN22 Trp620 risk allele is associated with increased frequency of CD127lowCD25+ Tregs in circulation. (A) Gating strategy
depicting the delineation of total CD127lowCD25hi Tregs in blood. Data were obtained by surface immunostaining of freshly isolated whole blood from 486 healthy
subjects selected by genotype from the Cambridge BioResource. (B–D) Scatter plots depict the frequency (geometric mean ± 95% CI) of: (i) CD127lowCD25hi Tregs
(B); (ii) CD45RA− CD127lowCD25hi memory Tregs (C); and (iii) CD45RA+ CD127lowCD25hi naive Tregs (D) in PTPN22 Arg620/Arg620 (N = 362; red), Arg620/Trp620 (N
= 85; blue), and Trp620/Trp620 (N = 39; green) donors. P-values were calculated by linear regression analysis. ns, not significant.
Trp620 risk allele could be altering T-cell activation potential
and response to an autoimmune reaction in Tregs, we
measured Treg frequency in fresh blood from our collection
of 486 healthy donors from the recall-by-genotype Cambridge
BioResource (CBR), where we were able to specifically obtain
blood samples from rare (<2% in populations of European
ancestry) Trp620/Trp620 homozygous individuals. Total Tregs
were defined in this study according to the expression of
the conventional Treg surface markers CD127 and CD25
(Figure 7A). We compared Treg frequencies in homozygous
(n = 39) and heterozygous (n = 85) carriers of the missense
Trp620 variant with homozygous carriers of the common PTPN22
genotype encoding Arg620/Arg620 (n = 362). We found that the
autoimmune PTPN22 Trp620 allele was significantly associated
with an increased frequency of CD127lowCD25hi Tregs in
blood (6.76, 7.05, and 7.94% in Arg620/Arg620, Arg620/Trp620,
and Trp620/Trp620 donors, respectively; Figure 7B), with an
estimated effect of 0.472% (Standard Error (SE) = 0.131; P =
3.3 × 10−4) increase in Treg frequency per copy of the minor
Trp620 missense allele (Table 2). We noted that the frequency of
Tregs in Arg620/Trp620 heterozygous donors was only marginally
increased compared to the common Arg620/Arg620 donors,
suggesting that two copies of the Trp620 missense allele may be
necessary for the observed phenotype. Furthermore, we observed
that the effect of the PTPN22 Trp620 allele was restricted to the
CD45RA− memory Treg subset (P = 1.0 × 10−4; Figure 7C),
with no significant association being detected with the frequency
of CD45RA+ naïve Tregs (Figure 7D).
To confirm this association we sought replication in a large
independent population-based cohort from Sardinia (n= 3,437).
Consistent with our findings, the PTPN22 Trp620 missense allele
was significantly associated with increased Treg frequency in
blood, with an estimated effect of 0.592% (SE = 0.177) per
copy of the minor allele (P = 5.9 × 10−4; Table 2). The larger
standard error in the replication set, in spite of much increased
sample size, is due to the fact that Trp620/Trp620 homozygotes
were not preferentially selected for as in the discovery set. The
fairly large allele frequency difference between the Sardinian
and UK populations may be due to differing levels of negative
selection, with a greater selective disadvantage to the Trp620
risk allele in Sardinia. A meta-analysis of the combined datasets
revealed an estimated increase of 0.514% in the frequency of
Tregs in circulation per copy of the autoimmunity associated
PTPN22 Trp620 allele (SE= 9.2× 10−3, Pcombined = 3.2× 10
−6;
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Table 2). Of note, analysis of the whole-blood eQTLGen database
(34) revealed that the PTPN22 Trp620 risk allele (rs247660C>T)
was associated with the increased expression of a number of
genes in different genomic loci (trans-eQTLs) in whole blood.
Interestingly, among the top most significantly associated genes
were several canonical Treg signature genes, such as CTLA4,
IL2RA, and FOXP3 (Supplementary Table 3). Gene ontology
(GO) pathway analyses revealed an over 100-fold enrichment in
terms associated with regulation of Treg differentiation, strongly
suggesting that the effect of the PTPN22 Trp620 missense allele
on the expansion of Tregs is sufficient to be manifested in the
expression of Treg genes in a highly heterogeneous whole-blood
dataset. Moreover, we have recently reported that PTPN22 is
strongly expressed in human Treg subsets compared to memory
Teff cells, and its expression was found to be strongly upregulated
upon in vitro activation, particularly in activated Treg subsets
(35). Consistently, we were able to detect increased PTPN22
expression in total CD4+ T cells isolated from IFNhi patients
(Supplementary Figurse 6C,E), suggesting that it could reflect
the expanded FOXP3+ Treg population in these patients.
To further validate that the increased frequency of total
CD4+ Tregs observed in whole blood was due to the expansion
of bona-fide thymically-derived HELIOS+FOXP3+ Tregs,
we next performed intracellular immunophenotyping from
cryopreserved PBMCs in a subset of healthy donors from the
CBR, including 40 rare PTPN22 Trp620/Trp620 homozygotes,
39 Arg620/Trp620 heterozygotes and 73 Arg620/Arg620 common
homozygotes, matched as closely as possible for age, sex
and time of sample collection. In support of an expanded
thymically-derived Treg population, we found that the
frequency of HELIOS+FOXP3+ Tregs was increased in
rare Trp620/Trp620 homozygous donors (4.32%) compared
to common Arg620/Arg620 homozygotes (3.75%, P =
0.041; Supplementary Figure 7), a subset that we have
previously shown to display a demethylated FOXP3 TSDR
(11). Similarly to HELIOS+FOXP3+ Tregs, we found an
increased frequency of the less abundant HELIOS−FOXP3+
Tregs (P = 0.047; Supplementary Figure 7), suggesting a
general increase in FOXP3+ memory Treg subsets in PTPN22
Trp620/Trp620 individuals.
Increased Expression of the Activation
Marker PD-1 in Carriers of the PTPN22
Trp620 Missense Allele Is Associated With
Reduced Treg Suppression Capacity and
Increased T-Cell Proliferative Capacity
In addition to the association with Treg frequency, we also
found a significantly increased frequency of PD-1+ cells
among the expanded CD45RA−FOXP3+HELIOS+ Tregs in
the rare Trp620/Trp620 donors (34.3%) compared to common
Arg620/Arg620 homozygotes (29.4%, P= 4.2× 10−3; Figure 8A).
Interestingly, we found a similar increase in the frequency
of PD-1+ cells among the CD45RA− Teffs in Trp620/Trp620
donors (P = 1.4 × 10−3; Figure 8B), suggesting that the
PTPN22 Trp620 variant is associated with increased T-cell
activation in both Tregs and Teffs. Furthermore, we noted
that the expression of PD-1 was highly correlated between
TABLE 2 | Genetic association of the PTPN22 Arg620Trp variant with Treg
frequencies in blood.
Cohort N MAF Effect
size
Standard
error
P-value
Discovery (UK) 486 0.088* 0.472 0.131 3.3 × 10−4
Replication (Sardinia) 3,437 0.020 0.592 0.177 5.9 × 10−4
Combined
(Meta-analysis)a
3,923 0.054** 0.514 9.2 × 10−3 3.2 × 10−6
Genetic association of the PTPN22 Arg620Trp (rs2476601) with peripheral Treg
frequencies. *From 91 GBR individuals in 1,000 genomes phase III. Frequency is 0.164
in the 486 individuals from our discovery cohort with genotypes passing QC due to the
targeted selection of rare homozygotes. **Mean of the two population frequencies, not
adjusting for sample size.
aMeta-analysis was performed using Fisher’s method for combining P-values and inverse-
variance weighting of parameter estimates. N, number of individuals with available
PTPN22 Arg620Trp genotypes; MAF, minor allele frequency.
CD4+ CD45RA− mTregs and mTeffs, and observed in all
PTPN22 genotype groups. These results were observed both on
the frequency of PD-1+ cells (Supplementary Figures 8A–C),
but also quantitatively on the expression levels of PD-
1 within PD-1+ cells (Supplementary Figures 8D–F). These
data indicate that even in healthy controls, which display
a noticeably lower frequency of PD-1+ cells compared to
SLE patients, the expression of PD-1 on CD4+ CD45RA− T
cells is a sensitive marker of immune activation and putative
ongoing inflammation.
To investigate if the increased expression of PD-1 in carriers
of the missense Trp620 allele was functionally associated with
their Treg suppression capacity in vitro, we sorted mTeffs
(CD4+CD45RA− CD127+CD25int−low) and autologous CD4+
CD127lowCD25hi Tregs from age- and sex-matched homozygous
Trp620 and Arg620 donors, and stimulated them with α-
CD2/3/28, before measuring mTeff proliferation after 6 days of
culture. We observed an apparent reduction in the amount of
suppression by Trp620 homozygous donors at two different ratios
of mTeff:Tregs (1:1 or 1:0.5) cells, P = 0.0360 and P = 0.0109,
respectively (Figure 8C).
These data lend further support to the hypothesis that Teff
hyperactivity and increased proliferative capacity in carriers of
the Trp620 variant renders them less amenable to suppression
by the autologous Tregs. Consistently, increased Teff cell
proliferation within a culture lacking Tregs correlated with less
suppression when Tregs were present (Figure 8D). Furthermore,
we found that Teff proliferation in Trp620 homozygous donors
was slightly increased after in vitro T-cell stimulation (P =
0.0302; Figure 8E). Similarly, CD4+CD127+CD25lowCD45RA+
naïve T cells from homozygous Trp620 donors also displayed
increased proliferation compared to their Arg620 counterparts (P
= 0.0270; Figure 8E). Taken together, these results suggest that
Trp620 affects T-cell proliferation, therefore providing a potential
mechanistic model supporting its genetic predisposition
to autoimmunity.
DISCUSSION
The clinical heterogeneity associated with SLE has been a
major challenge to our understanding of disease etiology and
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FIGURE 8 | T cells from PTPN22 Trp620/Trp620 donors display an activated phenotype and increased proliferative capacity. (A,B) Scatter plots depict the frequency
(geometric mean ± 95% CI) of PD-1+ cells within: (i) CD45RA− CD25hi FOXP3+HELIOS+ Tregs (A); and (ii) CD45RA− CD25int/low Teffs (B) from 152 healthy
volunteers recruited from the Cambridge BioResource. Data were stratified according to the genotype of the autoimmune-associated PTPN22 Arg620Trp variant.
(C) Treg suppressive capacity was assessed in a subset of 27 common Arg620 homozygous and 24 age- and sex-matched rare Trp620 homozygous donors by
measuring the proliferation of autologous CD45RA− CD25int/low T effector cells (mTeffs) in co-culture after in vitro activation for 6 days with anti-CD2/3/28 beads, at a
ratio of either 1:1 or 1:0.5 mTeff:Treg (D) Increased proliferation of mTeffs, in the absence of Tregs, from a given donor correlates with reduced suppression of mTeff
proliferation when autologous Tregs were present at a ratio of 1 mTeff: 0.5 Treg. (E) Proliferative capacity of CD45RA− memory Teffs and CD45RA+ naïve Teffs was
assessed after 6 days in vitro stimulation with anti-CD2/3/28 beads in the absence of Tregs in culture. P-values were calculated using two-tailed student’s t-tests
comparing the frequency of the assessed immune subsets between the PTPN22 Arg620/Arg620 and Trp620/Trp620 genotype groups. ns, not significant; mTeffs,
CD45RA− CD25int/low T effector cells; CPM, proliferation readings—[3H]thymidine incorporation rate (fmoles/g).
development of efficacious and long-lasting treatment options for
patients with this debilitating condition. To address this issue,
it is critical to develop better molecular diagnostic tools that
would allow the advent of a personalized medicine approach
in SLE. In this study, we have shed new light on the CD4+
FOXP3+ Treg compartment in SLE, and report an expansion of
this population in patients. Our findings are in agreement with
two previous publications reporting an expansion of thymically-
derived memory FOXP3+HELIOS+ Tregs in patients, which
was associated with increased disease activity (36, 37), and help
elucidate the conflicting results that have been reported in the
literature (8). Furthermore, we showed that FOXP3+ Tregs in
patients display an activated phenotype marked by the increased
frequency of PD-1+ cells, and their frequency was strongly
correlated with the circulating concentrations of both a type I
IFN marker, sSIGLEC-1, and IL-2. To our knowledge, this is
the first time that an association between increased FOXP3+
Treg frequency and IL-2 concentrations is reported in SLE
or in any other condition, in subjects not being treated with
recombinant IL-2. The development of technologies with fg-level
sensitivity (38) now provide the sensitivity to accurately measure
physiological concentrations of IL-2, revealing important new
insights into the regulation of IL-2 levels during the different
stages of disease. Notably, with the exception of the IL-2
concentrations, which we were only able to measure in cohort
2, these results were observed in both a clinic-attending and a
population-based cohort of patients not attending clinic and not
in need of urgent medication, suggesting that this association is
observed in both the active and remitting phases of the disease
and represent a marker of disease activity.
Previously, we have hypothesized that a subset of non-
conventional CD25lowFOXP3+ Tregs, which are found to be
increased in autoimmune patients, represents a terminal stage
on a continuum of Treg differentiation marked by the gradual
accumulation of immune activation/exhaustion markers such
as PD-1 and a concomitant loss of Treg suppressive markers
such as CTLA-4 and FOXP3 (11). In patients with active
autoimmune disease, chronic immune activation promotes the
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accumulation of PD-1+ CD25lowFOXP3+ Tregs as conventional
activated FOXP3+HELIOS+ CD25hi Tregs proliferate in an
attempt to regulate autoreactive Teff hyperactivity. In this study
we show that in addition to disease-specific mechanisms, the
autoimmune-associated PTPN22 Trp620 missense allele also
independently contributes to T-cell hyperactivity, marked by
increased expression of PD-1 and increased Teff proliferative
capacity. These data therefore support a Treg compensation
model, whereby the combination of disease-specific and
genetically-regulated predisposition for immune activation allow
Teffs to be activated more readily and produce more IL-2, which
would presumably promote Treg expansion. In SLE patients
prone to flaring, increased PTPN22 expression in activated CD8+
T cells is a biomarker of poor prognosis (17), which again
indicates an activated phenotype in flaring autoimmunity. These
data suggest that PTPN22 may also play an important regulatory
role in maintaining transcriptional stability and silencing IL-2
signaling in activated Tregs. One hypothesis is therefore that
the autoimmune-associated risk allele PTPN22 Trp620 could also
directly contribute to the functional differentiation of Tregs,
and the concomitant reduction in Treg suppressive capacity.
Consistent with this hypothesis, we observed that the association
between the PTPN22 Trp620 allele and increased Treg frequency
was restricted to the memory Treg compartment, and not on the
direct thymic output of naïve Tregs. However, we note that this
study was conducted in an adult population with a median age
of 55 years among rare PTPN22 Trp620/Trp620 donors, which
may limit our capacity to assess the role of this variant on
the generation of naïve CD45RA+ Tregs that are much more
abundant in younger individuals. In addition, further work is
required to test this functional mechanism and identify the direct
role of Trp620 on Teff and/or Treg function (as well as other cell
types) and their relative contribution to the observed increased
risk of autoimmunity and observed Treg frequency.
One limitation of the current study is that, due to the
lack of available surface-expressed markers, we were not
able to isolate CD25lowFOXP3+ Tregs from SLE patients to
test their putative suppressive capacity in vitro. However,
we note that the in vitro suppressive capacity of the
heterogeneous CD127lowCD25low population has previously
been demonstrated in humans, including in SLE patients
(13, 39). Furthermore, in this study, we also show that the
FOXP3 TSDR of HELIOS+FOXP3+ CD127lowCD25low T cells
is fully demethylated, which is consistent with their thymically-
derived Treg origin. Nevertheless, given that even in SLE patients
FOXP3+ cells represent at most 30–50% of the heterogeneous
CD127lowCD25low T-cell population, it is critical to identify
appropriate surface markers to unequivocally demonstrate the
suppressive capacity of the different CD25lowFOXP3+ T cell
subsets, particularly within the HELIOS− fraction.
In addition to T-cell intrinsic defects, the systemic type I IFN
production could provide an additional mechanism to reduce
Treg function in SLE patients. From an evolutionary perspective,
it is important that type I IFN signaling can induce a temporary
relief in the suppressive function of Tregs to promote an efficient
anti-viral Teff response (40). The suppressive effect of IFN-α on
Treg function has been shown to be mediated by the inhibition
of cAMP signaling, without any further effect on their phenotype
or TSDR demethylation profile (41). This mechanism has been
proposed to contribute to the reduced Treg differentiation in
SLE patients with an active type I IFN signature (42, 43), as
well as to the increased incidence of secondary autoimmunity
(44) and sustained reduction of Treg numbers (45) in patients
treated with IFN-α. In contrast, we show that the frequency of
FOXP3+ Tregs is strongly correlated with a type I IFN signature,
as assessed by the concentration of the monocyte/macrophage
activation biomarker sSIGLEC-1 (27). These data support a
disease model whereby the synergistic effect of Teff hyperactivity
and systemic IFN production impairs Treg function during flares
of disease activity.
It has been previously reported that CD4+ Teffs isolated
from SLE patients display a defect in IL-2 production when
stimulated in vitro, through the transcriptional repression of
the IL-2 gene (4, 46). Nevertheless, a longitudinal analysis of
SLE patients has shown that this IL-2 production impairment
could be relieved over the course of the disease—most notably in
response to immunosuppressive treatments (47). Furthermore,
it has been shown that the IL-2 secretion defect can be rescued
by resting the CD4+ T cells from SLE patients prior to re-
stimulation (48). Combined with our observation that circulating
levels of IL-2 are strongly associated with increased FOXP3+
Treg frequencies, these data suggest that the homeostatic balance
of IL-2 signaling is disrupted during disease flares in SLE patients.
We therefore hypothesize that during disease flares, the pro-
inflammatory changes promote increased CD4+ Teff function
and IL-2 production and override the reported in vitro defect in
IL-2 production by CD4+ Teffs. As a consequence, the expansion
of the CD4+ FOXP3+ Tregs due to elevated IL-2 concentrations
likely reflects an attempted compensatory mechanism to regulate
Teff cell hyperactivity in an inflammatory environment during
these periods of flaring autoimmunity. This is consistent with
recent data from patients with active relapsing-remittingmultiple
sclerosis where Teff hyperactivity mediated by increased IL-
6R signaling renders them resistant to Treg suppression (15).
Together, these data support a therapeutic strategy in chronic
relapsing autoimmune diseases, whereby temporary relief of
Teff function during flares of active disease by anti-IL-6R
or temporary T-cell immunoablation may be necessary to
promote disease remittance and restore immune regulation,
which could then be maintained through combination with low-
dose IL-2 therapy.
Given the recent success of Treg-directed therapies, including
low-dose IL-2 in SLE, and as more clinical trials move into
phase 2 and 3 (49, 50), a key unanswered question is how Treg
function and IL-2 homeostasis are restored. Currently, the studies
that have been conducted in SLE targeted only patients with
active disease and/or not responding to conventional standard-
of-care treatment options. However, the increased IL-2 levels in
SLE patients with active disease combined with our observation
that Tregs may be refractory to further IL-2 stimulation (38),
suggest that flaring SLE patients may not be the optimal
target patient group to treat with exogenous IL-2. Instead, we
hypothesize that low-dose IL-2 treatment could have maximal
effect in well-managed patients, to maintain IL-2 homeostasis
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and prevent the recurrence of disease flares. Furthermore, the
dosing regimen could also have profound effects in the efficacy of
these treatment options. Current dosing strategies are primarily
weekly treatment cycles of daily IL-2 treatment, adapted from
the original study by Saadoun et al. (51) using low-dose IL-
2 for the treatment of hepatitis C virus-induced vasculitis. We
have shown previously that Tregs isolated from T1D patients
treated with ultra-low doses of IL-2 are partially desensitized to
further IL-2 stimulation after 24 h (38), suggesting that such a
daily dosing schedule may not be the most efficient to promote
a functional Treg response. We note that, He et al. administered
IL-2 to patients every 2 days instead, which may have contributed
to the increased efficacy reported in the study (24). Low-dose IL-
2 studies and trials conducted to date in SLE were limited in
patient numbers, and therefore it is not possible to accurately
measure the specific impact of low-dose IL-2 or the non-specific
concurrent immunosuppression on the management of the
disease symptoms. Further trials in SLE and other autoimmune
diseases specifically designed to investigate the effect of low-dose
IL-2 on different stages of disease will be paramount to address
these questions.
A better understanding of the functional heterogeneity of the
Treg compartment and its modulation by IL-2 immunotherapy
could also provide a mechanistic rationale to explore novel
combination therapies to maximize the immunoregulatory
potential of low-dose IL-2 therapy. One example could be the
combination of IFN-α blockade, which is showing promise
in the clinic (52, 53), in combination with low-dose IL-2
treatment. Patients with the highest levels of type I IFN signaling
could benefit from short cycles of anti-IFN-α treatment during
peaks of disease activity to prevent the chronic activation of
the innate and adaptive immune response. Once in clinical
remission, these patients could then benefit from low-dose
IL-2 treatment instead, to maintain IL-2 homeostasis and
Treg function, while minimizing the potential serious side-
effects of blocking the IFN-α signaling pathway for long
periods of time. Similarly, checkpoint agonism therapies such
as PD-1 agonism could also be therapeutically beneficial in
autoimmune diseases, and are under active investigation in
early phase trials (54). Interestingly, PD-1 expression has
been shown to be increased on Tregs in response to low-
dose IL-2 treatment, and necessary for the maintenance of
Treg regulatory homeostasis (55). Moreover, PD-1 signaling
has been proposed to be central in maintaining Treg stability
and the maintenance of a FOXP3 transcriptional profile (56).
These data suggest that the combination of low-dose IL-2
immunotherapy with PD-1 agonism could be a promising
treatment option to selectively enhance the suppressive capacity
and regulatory homeostasis of the expanded Treg compartment,
while suppressing the proliferation of the pathogenic autoreactive
PD-1+ Teffs.
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